Please Wait
Applying Filters...
menu
    • menu
    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-12-22

    Virtual Booth

    An Enquiry

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    An Enquiry

    Menu

    Blarcamesine

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Anavex Provide Update on Regulatory Review in EU for Blarcamesine
    Anavex Provide Update on Regulatory Review in EU for Blarcamesine

    12 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/12/3204857/29248/en/Anavex-Life-Sciences-Provides-Update-on-Regulatory-Review-in-the-EU-for-Blarcamesine-to-Treat-Early-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    12 Dec 2025
    Share Share
    Anavex Presents Blarcamesine Data at 18th CTAD Conference
    Anavex Presents Blarcamesine Data at 18th CTAD Conference

    26 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/26/3195056/29248/en/Anavex-Life-Sciences-to-Present-Oral-Blarcamesine-Data-at-the-18th-Clinical-Trials-on-Alzheimer-s-Disease-CTAD-Conference.html

    GLOBENEWSWIRE
    26 Nov 2025
    Share Share
    Anavex Life Sciences Provides Regulatory Update on Blarcamesine
    Anavex Life Sciences Provides Regulatory Update on Blarcamesine

    14 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/14/3188222/29248/en/Anavex-Life-Sciences-Provides-Regulatory-Update-on-Blarcamesine-for-Early-Alzheimer-s-Disease.html

    GLOBENEWSWIRE
    14 Nov 2025
    Share Share
    Anavex Oral Blarcamesine Shows Ongoing Benefit in Alzheimer
    Anavex Oral Blarcamesine Shows Ongoing Benefit in Alzheimer

    29 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/29/3176310/29248/en/Anavex-Life-Sciences-Announces-Continued-Long-Term-Benefit-from-Oral-Blarcamesine-Compared-to-Decline-Observed-in-the-Alzheimer-s-Disease-Neuroimaging-Initiative-ADNI-Control-Group.html

    GLOBENEWSWIRE
    29 Oct 2025
    Share Share
    Anavex Life Sciences Presents At 35th Alzheimer Europe Conference
    Anavex Life Sciences Presents At 35th Alzheimer Europe Conference

    10 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/10/3164794/29248/en/Anavex-Life-Sciences-Announces-Presentation-at-the-35th-Alzheimer-Europe-Conference-Connecting-Science-and-Communities-The-Future-of-Dementia-Care.html

    GLOBENEWSWIRE
    10 Oct 2025
    Share Share
    Anavex Publishes Blarcamesine Ph IIb/III Alzheimer’s Results
    Anavex Publishes Blarcamesine Ph IIb/III Alzheimer’s Results

    30 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/30/3158599/29248/en/Anavex-Life-Sciences-Announces-Publication-of-Oral-Blarcamesine-Describing-a-New-Class-of-Clinical-Precision-Medicine-from-Phase-IIb-III-Alzheimer-s-Disease-Trial.html

    GLOBENEWSWIRE
    30 Sep 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.